Teva's Copaxone holds its own in wake of Mylan's generic price cut
admin 2nd August 2018 Uncategorised 0Mylan may have toppled list prices on its generic Copaxone, but Teva isn’t worried. After far surpassing expectations for the multiple sclerosis blockbuster in the second quarter, the Israeli drugmaker says it’s still on track to rake in significant sales this year.
More: Teva's Copaxone holds its own in wake of Mylan's generic price cut
Source: fierce